Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

BofA Securities has raised its rating on Bayer (ETR: BAYGN) to “buy” from “neutral,” increasing its price objective to €30 ...

Successful drug development is imperative to Bayer amid multiple challenges. The failure of a late-stage study on asundexian was a major setback for the company. BAYRY is also working to expand ...

Overall, asundexian was associated with a lower risk ... This study was supported by Bayer AG, Leverkusen, Germany. Alexander reported receiving grants, honoraria, or consulting fees from various ...